Drug intelligence / Profile preview

CLP-517

Development stage: Unknown
Lead developer: Charleston Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**CLP-517** is a Phase 1 fixed-dose small-molecule combination developed by Charleston Laboratories for severe acute pain requiring opioid analgesia and for prevention or reduction of opioid-induced nausea and vomiting. The formulation combines modified-release hydromorphone, a mu-opioid receptor agonist analgesic, with rapid-release promethazine, an H1 receptor antagonist with antiemetic activity and relatively weak dopamine-antagonist properties. ([charlestonlabs.com](https://charlestonlabs.com/pipeline/acute-pain/))

Other names: hydromorphone + promethazinehydromorphone/promethazinepromethazine + hydromorphonepromethazine/hydromorphone

Targets

DRD (Dopamine receptors)MOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on CLP-517.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLP-517.

Explore the full profile